Prof Saul Faust, co-study leader at the University of Southampton and a consultant paediatrician, said: “These latest results show that this long-acting antibody is safe and could protect thousands of babies from hospitalisation when used in conditions similar to routine clinical practice. It is really important information for the UK to help decide on options for the future national RSV immunisation programme.”
Trending
- 'Purely defensive' posture: Europe’s reluctant role in an expanding Middle East conflict
- Beyond oil and gas: Russia’s nuclear leverage explained
- Lenders lift mortgage rates as Middle East conflict continues
- Major VPN network to block ‘despised and despicable’ child sexual abuse material | Science, Climate & Tech News
- Anthropic vows to sue Pentagon over supply chain risk label
- Pas op met foto’s van je kind op sociale media: ‘Wat je online zet, gaat over jou, maar is niet meer van jou’
- Charity hopes new HQ can bring people together
- Diesel at 16-month high in UK as Iran war drives oil prices up further | Money News
